Sandu Pharmaceuticals Limited (524703) Fair Value & Analysis
Other · IN · Market cap ₹215M
Fair value as of: Jul 4, 2026
From 25 valuation models · updated today
Share price −2.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹30.52 – ₹50.66 · fair‑value band ₹31.80 – ₹53.00 · the ₹41.59 price screens below the ₹42.40 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sandu Pharmaceuticals Limited (524703) currently trades at ₹41.59, while our model-based Fair Value estimate is ₹42.40 — implying the stock looks roughly 1.9% undervalued today. We read business quality at 65/100 (solid quality), in the Other sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Sandu Pharmaceuticals Limited generated revenue of ₹477M at a net margin of 0.9%. Revenue declined 5.5% year over year. The stock trades on a trailing P/E of 44.1. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Sandu Pharmaceuticals Limited manufactures and markets ayurvedic medicines under the SANDU brand in India and internationally. The company offers medicines in the areas of cardiovascular, endocrine, digestive, genito-urinary, muscular-skeletal, nervous, male reproductive, and respiratory system. It also provides medicines for gynecological; nutrition; skin; and ear, nose, and throat disorders. The company was founded in 1899 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sandu Pharmaceuticals Limited reported revenue of ₹699M in FY2026 versus ₹655M in FY2022, a compound +1.7%/yr. Reported net income was ₹17.7M in FY2026, compounding +2.7%/yr from FY2022.
Is 524703 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €209.16 | -60% |
| Sony Corporation SON1 | €17.58 | €39.38 | +124% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $28.75 | +71% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Sandu Pharmaceuticals Limited (524703) undervalued?
What is the fair value of 524703?
What is the quality score of 524703?
What is the revenue of Sandu Pharmaceuticals Limited (524703)?
What is the net profit margin of 524703?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.